Revvity Valuation Analysis
| RVTY Stock | 99.30 0.35 0.35% |
Above Model Estimate
Today
The intrinsic value estimate for Revvity is based on a 3 months horizon. Lack of a positive P/E ratio suggests inconsistent earnings, which introduces uncertainty into valuation. Extending the time horizon generally improves valuation stability.
Cross-validating Revvity's valuation across DCF, multiples, and asset-based approaches reduces the risk of anchoring to one estimate. Relative valuation benchmarks Revvity's multiples against comparable companies in its sector. The optimal framework for Revvity combines bottom-up fundamental analysis with sector-relative analysis.
Main Profitability Drivers
The latest figures show Revvity's net profit margin at -4.09% and operating margin at 8.80%. The spread of 12.89 percentage points between the two margins reflects the impact of financing costs and tax obligations on Revvity's earnings. Revvity's revenue base of $2.86 billion yielded $1.58 billion in gross profit at a 55.2% gross margin, while net income came in at $241.2 million. The company produces -1.43% on shareholders' equity and -0.83% on total assets, framing Revvity's capital efficiency picture. The trend setup for Revvity is transitional, with some metrics improving even as the company continues to report negative margins. To dig further into these trends, see Revvity's detailed margin analysis to evaluate margin sustainability.
Price Book 1.57 | Gross Profit | Price Sales 3.89 | Profit Margin | Enterprise Value Revenue 4.75 |
Revvity Cash | $965.86 million |
Cash stood at $919.87 million as of December 31, 2025.
Revenue by Product
Revvity's disclosed product revenue mix spans 2 reported segments. Diagnostics contributes the largest disclosed amount at 390.07 million, while Life Sciences follows at 381.99 million. These disclosed segment amounts highlight relative scale across reported product lines without implying a complete reconciliation to total company revenue.Revvity is a biotechnology company where value is driven by research pipelines, clinical outcomes, and regulatory approvals, which directly shapes its valuation profile and margin structure. Classified as a turnaround stock in Life Sciences Tools & Services, negative margins indicate the investment case rests on restoring operational profitability. The sections below test current market pricing against capital structure, margins, and earnings trajectory.
Total Value Analysis
The current total-value analysis for Revvity points to enterprise value near 13.78 billion, market capitalization around 11.29 billion, debt of 3.52 billion, and cash and liquid equivalents of n/a as of latest reporting. The gap between enterprise value and market cap reflects the net effect of debt and cash — shifts in either can materially change the total-value picture.| Takeover Price | Market Cap | Debt Obligations | Cash & Equivalents |
13.78 billion | 11.29 billion | 3.52 billion |
Investor Information
About 100.0% of RVTY shares are owned by institutional investors. RVTY has price-to-book ratio of 1.57. A Price to Book (P/B) above 1.0 indicates the market assigns a premium to the equity, often reflecting expected growth or intangible value. Revvity has Price/Earnings To Growth (PEG) ratio of 0.62. RVTY had its last dividend issued on the 17th of July 2026. The firm completed a 2-for-1 stock split on 4th of June 2001. Operational scale and capital discipline leave Revvity with moderate financial flexibility with thin profitability. Operating returns remain positive, supporting continued earnings capacity.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 8.80% | 14.52% |
|
| |||||
| Total Cash From Operating Activities | $610.87 million | $581.78 million |
|
| |||||
| Operating Income | $268.69 million | $356.63 million |
|
|
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Revvity has an asset utilization ratio of 23.47 percent. This suggests that the Company is making USD0.23 for each dollar of assets. An increasing asset utilization means that Revvity is more efficient with each dollar of assets it utilizes for everyday operations.Macro event markers
Discounted Cash Flow Analysis
Revvity's custom levered DCF lands near 91.15 per share compared with market pricing around 98.95, leaving the stock above the modeled value. The market is pricing the shares around 7.9% over the model estimate. Current assumptions include 7.55% WACC, 4.0% perpetual growth, and about 551.29 Million of next-period free cash flow. Even with about 2.13 Billion of discounted forecast cash flow in the model, nearly 83.5% of enterprise value comes from the terminal value. With 83.5% of enterprise value concentrated in the terminal component, the estimate is inherently assumption-sensitive and should be interpreted as directional rather than precise.Model Value / Share
91.15
Equity value per share from the current custom levered DCF summary row.
Market Price
98.95
Current market price used by the same scenario.
Model Premium
7.9%
Market price sits above the model output.
WACC / LT Growth
7.55% / 4.0%
Forecast horizon: 2021 to 2030Terminal value share of EV: 83.5%
Revvity Market Price vs. Intrinsic Value
This chart compares observed market pricing with the model-derived equity value per share across forecast periods. It also illustrates the relative premium or discount, expressed as a percentage difference between market valuation and modeled intrinsic value.
Projected Revenue and Levered Free Cash Flow
Revenue and levered free cash flow projections are presented in billions, outlining the expected financial trajectory over the modeled horizon.
Key Model Assumptions
The inputs below reflect the core assumptions applied in the valuation model, including growth expectations, discount rates, and capital structure considerations.
| Input | Current Value |
|---|---|
| Weighted Average Cost of Capital | 7.55% |
| Long-Term Growth Rate | 4.0% |
| Cost of Equity | 9.03% |
| After-Tax Cost of Debt | 3.67% |
| Debt Weighting | 23.89% |
| Equity Weighting | 76.11% |
| Net Debt | 2.6 billion |
| Enterprise Value | 12.92 billion |
| Present Terminal Value | 10.78 billion |
| Terminal Value Share of EV | 83.5% |
Forecast Detail and Valuation Progression
This table presents the underlying forecast data used in the valuation, including revenue, cash flow generation, discounting effects, and the resulting per-share value across each projected period.
| Year | Revenue | Revenue Growth | Free Cash Flow | PV of LFCF | Equity Value / Share |
|---|---|---|---|---|---|
| 2021 | 3.83 billion | 0.00% | 1.32 billion | 0 | 90.78 |
| 2022 | 3.31 billion | -13.48% | 594.18 million | 0 | 90.40 |
| 2023 | 2.75 billion | -16.95% | 9.9 million | 0 | 94.21 |
| 2024 | 2.76 billion | 0.16% | 541.65 million | 0 | 90.13 |
| 2025 | 2.86 billion | 3.67% | 508.25 million | 0 | 90.28 |
| 2026 | 2.9 billion | 1.56% | 524.22 million | 487.41 million | 91.15 |
| 2027 | 2.92 billion | 0.66% | 527.69 million | 456.18 million | 91.15 |
| 2028 | 2.93 billion | 0.28% | 529.18 million | 425.34 million | 91.15 |
| 2029 | 2.93 billion | 0.12% | 529.81 million | 395.95 million | 91.15 |
| 2030 | 2.93 billion | 0.05% | 530.08 million | 368.33 million | 91.15 |
Profitability Analysis
Based on Revvity's financial statements, Revvity is generating positive operating income but reporting a net loss of 241.2 million, indicating that non-operating charges are eroding bottom-line results. The operating margin stands at 8.8% while the net profit margin is -4.09%, with return on equity at -1.43%. Profitability trends are mixed, with some indicators improving while others continue to contract.Net Income | First Reported 1985-09-30 | Previous Quarter 98.36 million | Current Value 40.72 million | Quarterly Volatility 70.13 million |
Macro event markers
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.00% | 48.07% |
|
| |||||
| Operating Profit Margin | 8.80% | 14.52% |
|
| |||||
| Pretax Profit Margin | 6.33% | 6.65% |
|
|
The profitability picture for Revvity starts with how effectively revenue converts to earnings. Net margin at -4.09% is negative despite positive operating margins of 8.8%, suggesting non-operating charges are eroding bottom-line profitability. The breakdown below connects margin levels with asset efficiency and capital returns. Revvity reports return on equity of -1.43%, but that reading should be interpreted cautiously because a reduced or negative equity base can distort ROE even when operating returns remain positive.
Earnings per Share Projection vs Actual
Tracking Revvity's EPS estimates over successive quarters reveals whether analyst conviction is strengthening or softening. Trailing EPS of 2.08 anchors the historical earnings baseline for Revvity. For Revvity, EPS is most informative alongside margin stability and cash-flow conversion. Consensus EPS estimates for Revvity represent the market's baseline earnings expectation. Deviations from this consensus on report day typically drive the sharpest price reactions. Revvity reported estimated earnings of 1.22 in earnings per share on 30th of June 2026. This estimate serves as the benchmark against which the next reported result will be judged by the market.Macro event markers
Earnings Estimation Breakdown
16 analysts contribute to the current consensus. The last reported EPS was 1.06 as of 31st of March 2026.
Last Reported EPS
1.19
Lowest
1.22
Expected EPS
1.25
Highest
Analyst estimate range around the current expected EPS projection.
Earnings Projection Consensus
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 16 | 93.51% | 1.06 | 1.22 | 2.08 |
Ownership Allocation
The majority of Revvity's outstanding shares are owned by institutional holders. These positions are typically held by large asset managers, pension funds, and index funds that manage capital on behalf of millions of clients. Institutions of this scale are required to disclose their holdings through 13F filings with the SEC, providing visibility into ownership changes each quarter.Revenue and Profit Overview
RVTY reported previous year's revenue of $2.86 billion. Net Income was $241.2 million with profit before overhead, payroll, taxes, and interest of $1.58 billion.Dividend Payment History
Market participants sometimes evaluate Revvity (RVTY) dividend patterns when assessing income potential. Dividend consistency is often evaluated alongside balance-sheet strength and operating margins. Those evaluating income potential may find it useful to analyze dividend distributions.
| 8th of May 2026 | ||
| 6th of February 2026 | ||
| 7th of November 2025 | ||
| 8th of August 2025 | ||
| 9th of May 2025 | ||
| 7th of February 2025 | ||
| 8th of November 2024 | ||
| 18th of October 2024 | ||
| 9th of August 2024 |
Reading the Current Signals
With margins currently negative, the business has not yet established consistent profitability, a dynamic that directly affects how sustainability of the current valuation is assessed.
Valuation Synthesis
Revvity operates as a lower-margin business where revenue scale and cost control are critical to value creation within the Life Sciences Tools & Services space. Operating income remains positive, although net profitability is still negative due to below-the-line charges. The negative ROE conflicts with otherwise positive margins, which usually points to a reduced or negative equity base rather than a deterioration in core operating economics. The data points to a business where current multiples are less informative because underlying profitability has not been established. The path forward depends on forward earnings expectations and sector dynamics.
For Revvity, the valuation signals above are most useful when compared against future developments as new data becomes available. With margins currently negative, the critical question is whether the path to profitability is supported by revenue trends and cost discipline.
Valuation Framework, Methodology & Assumptions
Revvity is a large-cap equity in Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Cycle exposure impacts valuation range. For Revvity, the leading valuation metrics are P/B of 1.57, P/S of 3.89; additional context comes from enterprise value (TTM) of 13.78 billion.
Revvity analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. Professional analyst research is incorporated when coverage is available. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.
Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.
The methodology combines multiple analytical inputs:
- Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
- Technical indicators - historical price patterns, momentum signals, and volatility measures
- Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
- Peer comparison - relative valuation against industry peers using standardized multiples
Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.
Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Growth Indicators
Growth investing in Revvity can be rewarding, but it usually depends on the market continuing to believe in above-average sales and earnings expansion. This framework is applicable when the question is whether the company can grow efficiently rather than simply grow quickly.
| Common Stock Shares Outstanding | 113.21 million | |
| Quarterly Earnings Growth Y O Y | 3.50% | |
| Forward Price Earnings | 18.6916 |
Revvity Current Valuation Indicators
A net-worth review of Revvity links market cap to balance-sheet health, cash flow, and implied growth expectations. Quantitative valuation narrows the range of reasonable outcomes by cross-referencing multiple model-based signals. Reported values are derived from company filings, audited financial statements, and market data, and are standardized within Macroaxis quantitative models for consistency. Model outputs reflect a point-in-time estimate based on available data and assumptions and should be interpreted alongside changes in operating performance, market conditions, and forward expectations.